Literature DB >> 30127670

Volumetric image-guided conformal radiotherapy for localized prostate cancer: Analysis of dosimetric and clinical factors affecting acute and late toxicity.

Gianluca Ingrosso1, Alessandra Carosi1, Daniela di Cristino1, Elisabetta Ponti1, Andrea Lancia1, Marta Bottero1, Alessandro Cancelli1, Alessandra Murgia1, Irene Turturici1, Riccardo Santoni1.   

Abstract

AIM: To identify factors influencing toxicity in patients affected by localized prostate cancer treated with conformal image-guided radiotherapy.
BACKGROUND: Image guidance in combination with conformal techniques is the standard of care in localized prostate cancer, but factors affecting toxicity are still under investigation.
MATERIALS AND METHODS: 294 patients were analyzed. Median age at diagnosis was 71 year. 76 Gy (38 × 2 Gy) were delivered to the target volume. We used the χ2 test to analyse associations between toxicity and dosimetric and clinical parameters. Multivariate analysis was performed using binary logistic regression. Kaplan-Meier method was used for survival analysis.
RESULTS: Median follow-up was 62.9 months. Acute grade ≥2 gastro-intestinal toxicity (GI) was 12.1%. Acute genito-urinary (GU) toxicity of grade ≥2 was 33.9%. Actuarial 4 and 5 years late grade ≥2 GI was 3% and 4%, respectively. Four and 5-year late grade ≥2 GU toxicity was 6% and 10%. At multivariate analysis for acute toxicity rectal V70 was correlated with GI toxicity (p = 0.01, HR 2.73 CI 1.19-6.26), and smoking habit with GU toxicity (p < 0.01, HR 2.50 CI 1.51-4.14). For late toxicity, rectal V70 was correlated with gastro-intestinal toxicity (p = 0.04, HR 4.76 CI 1.07-21.13), and pre-radiotherapy urinary symptoms with genito-urinary toxicity (p = 0.01, HR 2.84 CI 1.29-6.22). DISCUSSION: Conformal image-guided radiotherapy shows low rates of toxicity. Smoking should be avoided during radiotherapy. Besides the evaluation of high doses received by the organs at risk, individual factors, such as co-morbidities and lifestyle choices, have an impact on normal-tissue complication risk.

Entities:  

Keywords:  Cone-beam CT; Conformal radiotherapy; Prostate cancer; Toxicity; Volumetric image-guidance

Year:  2018        PMID: 30127670      PMCID: PMC6097402          DOI: 10.1016/j.rpor.2018.07.010

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  29 in total

Review 1.  What is the best way to radiate the prostate in 2016?

Authors:  Dominic H Moon; Jason A Efstathiou; Ronald C Chen
Journal:  Urol Oncol       Date:  2016-07-06       Impact factor: 3.498

2.  Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging.

Authors:  John M Schallenkamp; Michael G Herman; Jon J Kruse; Thomas M Pisansky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

3.  Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity-modulated radiotherapy.

Authors:  Lu Wang; Peter Hoban; Kamen Paskalev; Jie Yang; Jinsheng Li; Lili Chen; Weijun Xiong; Charlie C M Ma
Journal:  Med Dosim       Date:  2005       Impact factor: 1.482

4.  Intensity-modulated and 3D-conformal radiotherapy in hypofractionated prostate cancer treatment using Elekta Beam Modulator™ micro-MLC: A dosimetric analysis.

Authors:  Alessandra Carosi; Gianluca Ingrosso; Elisabetta Ponti; Andrea Lancia; Riccardo Santoni
Journal:  Acta Oncol       Date:  2015-06-09       Impact factor: 4.089

5.  70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.

Authors:  Véronique Beckendorf; Stéphane Guerif; Elisabeth Le Prisé; Jean-Marc Cosset; Agnes Bougnoux; Bruno Chauvet; Naji Salem; Olivier Chapet; Sylvain Bourdain; Jean-Marc Bachaud; Philippe Maingon; Jean-Michel Hannoun-Levi; Luc Malissard; Jean-Marc Simon; Pascal Pommier; Men Hay; Bernard Dubray; Jean-Léon Lagrange; Elisabeth Luporsi; Pierre Bey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-14       Impact factor: 7.038

6.  Preliminary experience of a predictive model to define rectal volume and rectal dose during the treatment of prostate cancer.

Authors:  M D Falco; M D'Andrea; D Fedele; R Barbarino; M Benassi; E Giudice; E Hamoud; G Ingrosso; P Ladogana; F Santarelli; G Tortorelli; R Santoni
Journal:  Br J Radiol       Date:  2011-09       Impact factor: 3.039

7.  Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Authors:  Stephanie T H Peeters; Wilma D Heemsbergen; Wim L J van Putten; Annerie Slot; Hans Tabak; Jan Willem Mens; Joos V Lebesque; Peter C M Koper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

8.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

Authors:  Michael J Zelefsky; Marisa Kollmeier; Brett Cox; Anthony Fidaleo; Dahlia Sperling; Xin Pei; Brett Carver; Jonathan Coleman; Michael Lovelock; Margie Hunt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

9.  Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer.

Authors:  Karin B Dieperink; Steinbjørn Hansen; Lis Wagner; Christoffer Johansen; Klaus K Andersen; Olfred Hansen
Journal:  Acta Oncol       Date:  2012-07       Impact factor: 4.089

10.  The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397).

Authors:  G C Barnett; G De Meerleer; S L Gulliford; M R Sydes; R M Elliott; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2011-04-05       Impact factor: 4.126

View more
  1 in total

1.  Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.

Authors:  Leif-Erik D Schumacher; Alan Dal Pra; Sarah E Hoffe; Eric A Mellon
Journal:  Br J Radiol       Date:  2020-08-12       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.